tbuckley/cabot-search huggingface dataset:
Abstract 989: Profiling the expression of SGLT1 in prostate cancer
Authors: Alicia Blessing, Zhang Weihua
Journal: Cancer Research (2011)

Abstract Upregulation of the epidermal growth factor receptor (EGFR; HER1; erbB1), a receptor tyrosine kinase, has been linked with increased cell proliferation and decreased apoptosis and thus, with poor prognosis for cancer patients. EGFR has been found to be over-active in most tumors of epithelial origin including: non-small cell lung cancer, breast, head and neck, gastric, colorectal, esophageal, prostate, bladder, renal, pancreatic, and ovarian cancers. EGFR is elevated in prostate cancer cells along disease progression. EGFR tyrosine kinase inhibitors failed to show beneficial effects for prostate cancer patients. Previous studies have found EGFR has kinase independent prosurvival functions. Independent of its kinase activity, EGFR participates in the maintenance of the basal intracellular glucose level of cancer cells by interacting with and stabilizing SGLT1, thus preventing cancer cells from autophagic death. EGFR and SGLT1 do physically interact; however, it was previously unknown whether SGLT1 expression is upregulated along prostate cancer progression. Sodium-dependent glucose co-transporters (SGLTs) are transmemebrane glucose transporter proteins involved in the active transport of glucose. An antibody against human SGLT1 was made and used with immunohistochemistry to show in this preliminary study that SGLT1 is exclusively expressed in the hyperplastic and malignant prostate epithelial cells. SGLT1 was not expressed in the normal epithelial or BPH cells. The results from this study indicate that as the disease progresses, the increased need for glucose within the cells is at least in part being met by the continuous activity of the sodium-dependent glucose co-transporter 1. This potential role of SGLT1 in prostate cancer may provide avenues for new prostate cancer treatments. Future endeavors will focus on designing interfering peptides that ideally will interfere with the SGLT1/EGFR binding, destabilizing SGLT1 in prostate cancer cells, and promoting cell death of prostate cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 989. doi:10.1158/1538-7445.AM2011-989
P3-01-12: Prognostic Impact of RANK, RANKL and OPG Gene Expression in ER Positive Primary Breast Cancer.
Authors: E Ruckhaeberle, V Mueller, M Schmidt, N Saenger, L Hanker, R Gaetje, A Ahr, U Holtrich, T Karn, A Rody, M Kaufmann
Journal: Cancer Research (2011)

Abstract Background The cell surface receptor RANK (receptor activator of NFκB), its ligand (RANKL) and the decoy receptor of RANKL osteoprotegerin (OPG) play an important functional role in bone physiology and in bone metastasis by regulating osteoclasts. Just recently it was shown that tumor-infiltrating lymphocytes can stimulate breast cancer metastases through RANK-RANKL signalling. Material and methods: We analyzed gene expression of RANK, RANKL and OPG in a combined Affymetrix dataset of 307 ER positive breast cancers from our institutions which were either untreated of treated with chemotherapy. Kaplan Meier analysis of disease free survival and Cox regression analysis was applied to examine the prognostic value of the different markers. Results: We observed no significant difference in survival when samples were analyzed according to either RANK or RANKL mRNA expression. In contrast when samples were stratified in quartiles of OPG expression a positive linear relationship of survival with the expression of OPG was observed. Moreover since OPG demonstrated a bimodal type of expression a cutoff value can be derived from the expression data. Using this cutoff value a hazard ration of 2.14 (95% CI 1.27−3.61; P=0.004 for low OPG expression was detected. OPG expression correlated with lower proportion of grade 3 tumors (15.7% vs 27%; P=0.022) and a higher proportion of PgR positive samples (86.2% vs 71.4%; P=0.002). No significant differences were observed for lymph node status, age, tumor size and HER2 status. In multivariate analysis only lymph node status remained significant while OPG, Ki67, age, grade, and PgR only displayed a trend towards significance. Conclusion: Expression of osteoprotegerin seems to correlate with good prognosis in ER postive breast cancer. These data are in line with in vitro studies demonstration that OPG inhibits RANKL induced migration of tumor cells. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-01-12.
Abstract 328: An integrated analysis of three distinct IBC/non-IBC Affymetrix gene expression data sets to study the transcriptional heterogeneity both between IBC and non-IBC and within IBC
Authors: Steven J. Van Laere, Naoto Ueno, Pascal Finetti, Peter B. Vermeulen, Anthony Lucci, Daniel Birnbaum, Fredika Robertson, Takayuki Iwamoto, Peter Van Dam, Wendy Woodward, Patrice Viens, Luc Y. Dirix, James Reuben Reuben, François Bertucci
Journal: Cancer Research (2011)

Abstract Introduction. Several studies have applied gene expression profiling to inflammatory breast cancer (IBC). Most of these studies were underpowered, mainly because IBC is a rare disease and hence, IBC sample sizes are small. Here, we present an integrated analysis of three distinct gene expression data sets of IBC and non-IBC samples – thus with enhanced power – to further uncover the IBC-specific molecular biology. Materials &amp; Methods. Three Affymetrix gene expression data sets of 137 IBC and 252 non-IBC samples were integrated. Data were normalized, and genes with high signal-to-noise ratios in at least 1% of the arrays were filtered in. The samples were classified according to their molecular subtypes. IBC-specific heterogeneity was investigated using hierarchical clustering, coupled with silhouette score analysis. Supervised analysis, comparing IBC with non-IBC, was performed in non-stage-matched, stage-matched, and molecular subtype-matched approaches with global testing. IBC-specific activated pathways, miRNA-families, and transcription factors were identified with a target gene analysis approach. Results. Four robust IBC sample clusters were identified, clearly associated with the molecular subtypes, with a predominance of the combined Basal-like, ErbB2+, and Luminal B subtypes (∼70% vs. ∼40% in non-IBC; P&amp;lt;0.0001). When we compared IBC to non-IBC, stage-matched and non-stage-matched differences were identified (global test, P&amp;lt;0.0001). After comparing IBC with non-IBC samples within each of the molecular subtypes, differences persisted only within the luminal A and normal-like subtypes (global test, P&amp;lt;0.0001 and P=0.046, respectively). Target gene analysis identified two molecular pathways (TGFβ and INFα), 16 transcription factors (e.g. NKX2.2, FOXM1), and 10 miRNA families that were differentially activated in IBC and non-IBC (FDR&amp;lt;0.01) but not in the four identified IBC sample clusters. Conclusions. This meta-analysis demonstrates that IBC is indeed transcriptionally heterogeneous and that differences between IBC and non-IBC are predominated by the differences in the distribution of the molecular subtypes between IBC and non-IBC. Taking this into account, we were able to more accurately spot IBC-specific changes in pathway, miRNA, and transcription factor activation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 328. doi:10.1158/1538-7445.AM2011-328
185 THE PROTECT STUDY: EVEROLIMUS MONOTHERAPY vs. CALCINEURIN INHIBITOR-BASED THERAPY RESULTS IN PROGRESSIVE RENAL FUNCTION BENEFIT OVER 35 MONTHS IN LIVER TRANSPLANT RECIPIENTS
Authors: M. Sterneck, G. Kaiser, N. Richter, N. Heyne, F. Rauchfuss, P. Neuhaus, P. Schemmer, L. Fischer, E.M. Paulus, M. Mertens, H.J. Schlitt
Journal: Journal of Hepatology (2013)
Case 17-2009
Authors: David M. Greer, Robert P. Friday, Javier Romero, Pavan K. Auluck
Journal: New England Journal of Medicine (2009)

A 30-year-old man was admitted to this hospital because of progressive neurologic deficits, which had begun 1 year earlier with headaches and word-finding difficulties, followed by seizures and cognitive and motor deficits. Imaging studies revealed progressive lesions involving predominantly the white matter, basal ganglia, and brain stem. He had a history of painful genital and oral ulcers, associated with arthralgias, for which immunosuppressive medications had been given. A diagnostic procedure was performed.
Abstract 1770: Overexpression of fibroblast growth factor receptor 2 (FGFR2) in gastric cancer and basis for future FGFR2-targeted cancer therapy
Authors: Kun-Huei Yeh, Chia-Tung Shun, Chiu-Hua Kao, Yu-Lin Lin, Ying-Chun Shen, Ann-Lii Cheng
Journal: Cancer Research (2010)

Abstract Introduction: Fibroblast growth factors (FGFs) are potent mitogens and inducers of angiogenesis. FGF signalling pathway is closely associated with cancer development and progression. Fibroblast growth factor receptor 2 (FGFR2) gene, located at human chromosome 10q26, encodes FGFR2b and FGFR2c isoforms functioning as distinct FGF receptors. Gene amplification or missense mutation of FGFR2 occurs in gastric cancer (GC). Genetic alterations of FGFR2 may induce aberrant activation of FGFR2 signalling pathway, thereafter induce proliferation and survival of GC cells. FGFR2 plays an important role in gastric carcinogenesis. Patients and Methods: A total of 33 gastric cancer tissues with formalin-fixed, paraffin-embedded tumor slides were investigated by immunohistochemical staining with primary antibody against FGFR2. By Lauren's classification, there are 9 diffuse-type, 23 intestinal-type, and 1 mixed-type GC patients, respectively. Results: The FGFR2 immunohistochemical staining was classified as 0, 1+, 2+, and 3+ according to percentage of immunoreactive positive-staining FGFR2 cells in &amp;lt;10%, 10-25%, 25-50%, and &amp;gt;50% tumor cells, respectively. The relationship between the FGFR2 expression and the clinicopathological characteristics were analyzed. Among 33 GC patients, 13 patients (39.4%; 23-57%, 95% C.I.) had FGFR2 expression (1+, 2+, and 3+), and 11 patients (33.3%; 17-52%, 95% C.I.) had FGFR2 overexpression (2+ and 3+), respectively. FGFR2 expression was not correlated with diffuse-type versus intestinal-type GC patients (p=0.427, Fisher exact test). Conclusions: Overexpression of FGFR2 in gastric cancer forms the basis of the rational clinical application of future FGFR2-targeted cancer therapy for treatment of advanced GC. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1770.
FRI0304 Treatment of knee osteoarthritis with intra-articular infliximab improves total womac score. High baseline levels of synovial cellularity predict improvement
Authors: H.B. Lindsley, J. Schue, O. Tawfik, R. Bolce, D.D. Smith, G. Hinson, J.A. Wick
Journal: Annals of the Rheumatic Diseases (2013)

Post-adenotonsillectomy pulmonary edema (pATPE) is a life-threatening condition that necessitates immediate clinical intervention. The early diagnosis and detection of the signs of this condition is vital to its treatment and patient outcome. The purpose of this review article is to present epidemiological data on the prevalence of pATPE, and address the mechanisms of development, types, etiology, pathophysiology, and management of pATPE. In order to minimize postoperative intensive care unit admission rates of pATPE, utilization of preoperative clinical assessment, operative/postoperative monitoring tools, and procedural precautions are discussed.
BASELINE AND SERIAL EXAMINATION OF THE RVOT DOPPLER FLOW PROFILE PREDICTS THE DEGREE OF PULMONARY VASCULAR OBSTRUCTION PRE AND POST THROMBOLYSIS IN ACUTE SUBMASSIVE PE
Authors: Yevgeniy Brailovsky, Farhan Raza, Vladimir Lakhter, Estefania Oliveros, Scott Simpson, Chandra Dass, Vikas Aggarwal, Riyaz Bashir, Paul Forfia
Journal: Journal of the American College of Cardiology (2015)
Malignant Pheochromocytoma Metastasis to the Breast Shown on I-123 MIBG Scan
Authors: Mihir Patel, Peter Santos, Ian Jong, Dee Nandurkar, John McKay
Journal: Clinical Nuclear Medicine (2010)

A 36-year-old woman was referred to our department for I-123 metaiodobenzylguanidine (MIBG)-SPECT/CT scan 3 years after surgical excision of pheochromocytoma. She was referred due to recurrence of her symptoms as well as raised urinary catecholamines. Review of I-123 MIBG scan revealed multiple MIBG-avid metastatic lesions. Most of these were bony lesions, however, there were also 2 soft tissue lesions in the left breast. She subsequently underwent ultrasound-guided fine-needle aspiration of the left breast lesions. Fine-needle aspiration revealed cytologic changes consistent with pheochromocytoma. There has only been 1 previous reported case of pheochromocytoma metastasizing to the breast. This is the first case in which the metastasis was detected by I-123 MIBG scan.
Improvement of Renal Function with Selective Thromboxane Antagonism in Lupus Nephritis
Authors: Alessandro Pierucci, Bianca M. Simonetti, Gabriella Pecci, Giorgio Mavrikakis, Sandro Feriozzi, Giulio A. Cinotti, Paola Patrignani, Giovanni Ciabattoni, Carlo Patrono
Journal: New England Journal of Medicine (1989)

To test the hypothesis that the vasoconstrictor thromboxane A2 may affect renal hemodynamics in lupus nephritis, we examined the short-term effects of a selective thromboxane-receptor antagonist, BM 13,177, and of low-dose aspirin. In a randomized, double-blind, crossover study, 10 patients with biopsy-proved lupus nephritis were given a 48-hour continuous infusion of BM 13,177 or placebo. At base line, seven patients had markedly elevated urinary levels of thromboxane B2, the breakdown product of thromboxane A2. During the infusion of BM 13,177, the inulin clearance rate, which was 68 ml per minute per 1.73 m2 of body-surface area at base line, increased by an average of 24 percent (range, 12 to 47 percent; P<0.01). Para-aminohippurate clearance was increased to the same extent, with no change in the filtration fraction. The bleeding time doubled, indicating an occupancy of platelet thromboxane receptors of more than 95 percent. The hemodynamic changes were associated with a significant increase in sodium excretion from 76 to 118 mmol per day (P<0.01) but with no change in arterial blood pressure. In another study, 10 additional patients with lupus nephritis were randomly assigned to receive either placebo or 20 mg of aspirin twice daily for four weeks. The aspirin regimen produced a selective, cumulative inhibition of platelet cyclooxygenase activity and a doubling of bleeding time. However, there was no change in the inulin clearance rate and no change in urinary levels of thromboxane B2 or 6-keto-prostaglandin F1α, which are indicators of renal synthesis of thromboxane A2 and prostacyclin, respectively. We conclude that in lupus nephritis, impairment of renal function is at least in part mediated hemodynamically and is reversible with a thromboxane antagonist. Platelets, however, are not a major source of THROMBOXANE A2 synthesis and action within the kidney. (N Engl J Med 1989; 320:421–5.)
LENGTH OF STAY AND HOSPITALIZATION COSTS OF MULTIVESSEL PERCUTANEOUS CORONARY INTERVENTION IN HEMODYNAMICALLY STABLE PATIENTS PRESENTING WITH ST ELEVATION MYOCARDIAL INFARCTION
Authors: Nilay Patel, Sidakpal Panaich, Shilpkumar Arora, Chirag Savani, Sopan Lahewala, Nileshkumar Patel, Carlos Gongora, Abhishek Deshmukh, Apurva Badheka
Journal: Journal of the American College of Cardiology (2016)
Does Increased Access to Primary Care Reduce Hospital Readmissions?
Authors: Morris Weinberger, Eugene Z. Oddone, William G. Henderson
Journal: New England Journal of Medicine (1996)

For chronically ill patients, readmission to the hospital can be frequent and costly. We studied the effect of an intervention designed to increase access to primary care after discharge from the hospital, with the goals of reducing readmissions and emergency department visits and increasing patients' quality of life and satisfaction with care.
Gastrointestinal bleeding from jejunal heterotopic pancreas diagnosed by deep small-bowel enteroscopy
Authors: J. Williamson, David Gonzalo, Juan Alvarez, Georgios Rossidis, Peter Draganov
Journal: Endoscopy (2014)

A 70-year-old man presented with a 2-week history of overt (melena) and obscure gastrointestinal bleeding requiring an 8-unit blood transfusion. He underwent upper gastrointestinal endoscopy, colonoscopy, and push enteroscopy, all of which were nondiagnostic. A video capsule endoscopy, which reached the cecum at 6 hours and 21 minutes, showed active bleeding at 2 hours and 18 minutes without an obvious underlying lesion.
Awards, Appointments, Announcements
Authors: W. P. McWhorter
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Awards, Appointments, Announcements Get access William P. McWhorter, M.D., William P. McWhorter, M.D., Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 18, 16 November 1988, Pages 1440–1441, https://doi.org/10.1093/jnci/80.18.1440 Published: 16 November 1988
Abstract SY25-03: Haploinsufficiency in cancer: When half simply isn't good enough.
Authors: Nicole Solimini, Natalya N. Pavlova, Craig Mermel, Qikai Xu, Anna E. Burrows, Ji Luo, Mamie li, Rameen Beroukhim, Matthew Meyerson, Stephen J. Elledge
Journal: Cancer Research (2013)

Abstract Breast cancer is a collection of diseases with distinct clinical behaviors and underlying genetic causes. We have searched genetically for genes that have cancer relevant phenotypes including genes that alter cellular proliferation, cellular transformation, cell survival, cellular senescence, and genes that are essential for the proliferation of cancer cells. We have approached this by the generation of libraries of shRNAs for loss of function experiments and libraries of ORFs for gain of function experiments. We will discuss these technologies and how they can be applied to the functional dissection of genes important for breast cancer. Using these technologies, we found evidence for wide-spread haploinsufficiency in cancer due to recurring hemizygous deletions. We propose a tumor suppressor hypothesis called the Cancer Gene Island model whereby, hemizygous deletions selledge regions containing a high density of negative growth regulators (STOP genes) and a low density of essential genes (GO genes). The deletions provide a proliferative advantage to cells through cumulative haploinsufficiency. Citation Format: Nicole Solimini, Natalya N. Pavlova, Craig Mermel, Qikai Xu, Anna E. Burrows, Ji Luo, Mamie li, Rameen Beroukhim, Matthew Meyerson, Stephen J. Elledge. Haploinsufficiency in cancer: When half simply isn't good enough. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr SY25-03. doi:10.1158/1538-7445.AM2013-SY25-03
Radioimmunoscintigraphy With Tc-99m Labeled Monoclonal Antibody 170H.82 in Suspected Primary, Recurrent, or Metastatic Breast Cancer
Authors: PETER LIND, HANS-JÜRGEN GALLOWITSCH, PETER MIKOSCH, EWALD KRESNIK, IRIS GOMEZ, JOHANN OMANN, HANS-PETER DINGES, GRAEME BONIFACE
Journal: Clinical Nuclear Medicine (1997)

Radioimmunoscintigraphy (RIS) with Tc-99m labeled 170H.82, an intact murine monoclonal antibody (MAb) was performed in 27 patients with suspected primary, recurrent, or metastatic breast cancer. For radioimmunoimaging the authors used a double-headed, high-resolution gamma camera. The lesions detected by RIS were evaluated by histopathology, and for metastatic disease by CT, MRI, and bone scan. If the evaluation was made lesion by lesion, RIS with Tc-99m MAb 170H.82 showed 23 true-positive results, 3 false-negative results, 9 true-negative results, 3 false-positive results for primary and recurrent disease; sensitivity was 88% and specificity was 75%. In patients with distant metastases, detection rate was 67% (12 true-positive results and 6 false-negative results). All patients had normal baseline values for human anti-mouse antibodies (HAMA) and 6 weeks after RIS with 3 mg MAb, only 2 of 23 patients had developed a HAMA response (9%). No adverse effects were observed. The authors' clinical experience shows that RIS with MAb 170H.82 is a valuable additional method for detecting breast cancer, especially in patients with uncertain primaries or scar tissue after breast conserving treatment in which differential diagnosis is very difficult.
Abstract 243: Characterization of CDK5RAP3 in hepatocellular carcinoma
Authors: Grace W.Y. Mak, Irene O.L. Ng, Y.p. Ching
Journal: Cancer Research (2010)

Abstract CDK5 regulatory subunit associated protein 3 (CDK5RAP3, also called C53 and LZAP) is a novel cyclin-dependent kinase 5 (CDK5) activator interacting protein that has been shown to regulate apoptosis induced by genotoxic stress. More recently, CDK5RAP3 has also been found to regulate p53 and NF-κB signaling. Here, we have characterized the role of CDK5RAP3 in hepatocellular carcinoma (HCC) cell lines. Using real-time quantitative RT-PCR, we found that 58% (39/67) of human HCC samples had significantly higher expression (at least 2-fold) of CDK5RAP3 transcripts as compared to their corresponding nontumorous livers. The overexpression of CDK5RAP3 was statistically correlated with clinicopathological feature of more metastatic phenotype. Using stable expression clones, we demonstrated that knockdown of CDK5RAP3 in HCC cell line inhibited anchorage-independent growth and tumorigenicity of cells while overexpression of CDK5RAP3 remarkably promoted tumorigenicity of cells. Our western blotting data indicated that knockdown of CDK5RAP3 in HCC cell line SMMC-7721 resulted in an upregulation of p14ARF. Using luciferase reporter assay, we showed that ectopic expression of CDK5RAP3 suppressed p14ARF promoter activity in a dose-dependent manner. Taken together, our data provide the first evidence that CDK5RAP3 is overexpressed in HCC and overexpression of CDK5RAP3 may contribute to the development of HCC via downregulation of p14ARF. In summary, CDK5RAP3 is a potential oncoprotein in promoting hepatocarcinogenesis, the regulation behind may attribute to its regulation on p14ARF expression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 243.